Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.

Schoepfer AM, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, Fournier N, Vader JP, Burnand B, Michetti P, Froehlich F.

Aliment Pharmacol Ther. 2014 Oct;40(8):930-7. doi: 10.1111/apt.12929. Epub 2014 Aug 22.

2.

Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.

Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Aug;8(8):825-34. doi: 10.1016/j.crohns.2013.12.026. Epub 2014 Jan 22.

PMID:
24462322
3.

When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.

Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACT-II Update Panellists.

J Crohns Colitis. 2013 Nov;7(10):820-6. doi: 10.1016/j.crohns.2013.04.013. Epub 2013 May 9.

PMID:
23664620
4.

Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II.

Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):257-63. doi: 10.1016/j.crohns.2009.03.008. Epub 2009 May 14.

PMID:
21172284
5.

Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II.

Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F, Michetti P; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):250-6. doi: 10.1016/j.crohns.2009.06.001. Epub 2009 Aug 22.

PMID:
21172283
6.

Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II.

Juillerat P, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Bemelman WA, Lémann M, Oresland T, Michetti P, Froehlich F; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):241-9. doi: 10.1016/j.crohns.2009.05.002. Epub 2009 Jul 14.

PMID:
21172282
7.

Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II.

Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):232-40. doi: 10.1016/j.crohns.2009.05.003. Epub 2009 Jul 15.

PMID:
21172281
8.

Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group.

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1352-7. Erratum in: Eur J Gastroenterol Hepatol. 2011 Mar;23(3):294. Tempia-Caliera, Michela [corrected to Schäppi, Michela].

PMID:
20964261
9.

Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.

Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2010 Oct;32(8):1007-16. doi: 10.1111/j.1365-2036.2010.04434.x. Epub 2010 Aug 18.

10.

Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort.

Juillerat P, Pittet V, Mottet C, Felley C, Gonvers JJ, Vader JP, Burnand B, Froehlich F, Wolters FL, Stockbrügger RW, Michetti P; EC-IBD Group.

Scand J Gastroenterol. 2010 Dec;45(12):1449-56. doi: 10.3109/00365521.2010.505660. Epub 2010 Jul 26.

PMID:
20653489
11.

Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.

Gonvers JJ, Heim MH, Cavassini M, Müllhaupt B, Genné D, Bernasconi E, Borovicka J, Cerny A, Chave JP, Chuard C, Dufour F, Dutoit V, Malinverni R, Monnat M, Negro F, Troilliet N, Oneta C.

Swiss Med Wkly. 2010 Jul 19;140:w13055. doi: 10.4414/smw.2010.13055. eCollection 2010.

12.

The effect of nonmedical factors on variations in the performance of colonoscopy among different health care settings.

Lamiraud K, Holly A, Burnand B, Juillerat P, Wietlisbach V, Froehlich F, Gonvers JJ, Vader JP.

Med Care. 2010 Feb;48(2):101-9. doi: 10.1097/MLR.0b013e3181c160ee.

PMID:
20068487
13.

Appropriateness of colonoscopy in Europe (EPAGE II). Presentation of methodology, general results, and analysis of complications.

Juillerat P, Peytremann-Bridevaux I, Vader JP, Arditi C, Schusselé Filliettaz S, Dubois RW, Gonvers JJ, Froehlich F, Burnand B, Pittet V.

Endoscopy. 2009 Mar;41(3):240-6. doi: 10.1055/s-0028-1119643. Epub 2009 Mar 11. Review.

PMID:
19280536
14.

Appropriateness of colonoscopy in Europe (EPAGE II). Functional bowel disorders: pain, constipation and bloating.

Schusselé Filliettaz S, Gonvers JJ, Peytremann-Bridevaux I, Arditi C, Delvaux M, Numans ME, Lorenzo-Zúñiga V, Dubois RW, Juillerat P, Burnand B, Pittet V, Vader JP, Froehlich F; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):234-9. doi: 10.1055/s-0028-1119625. Epub 2009 Mar 11. Review.

PMID:
19280535
15.

Appropriateness of colonoscopy in Europe (EPAGE II). Iron-deficiency anemia and hematochezia.

Peytremann-Bridevaux I, Arditi C, Froehlich F, O'Malley J, Fairclough P, Le Moine O, Dubois RW, Gonvers JJ, Schusselé Filliettaz S, Vader JP, Juillerat P, Pittet V, Burnand B; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):227-33. doi: 10.1055/s-0028-1119644. Epub 2009 Mar 11. Review.

PMID:
19280534
16.

Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease.

Schusselé Filliettaz S, Juillerat P, Burnand B, Arditi C, Windsor A, Beglinger C, Dubois RW, Peytremann-Bridevaux I, Pittet V, Gonvers JJ, Froehlich F, Vader JP; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):218-26. doi: 10.1055/s-0028-1119627. Epub 2009 Mar 11. Review.

PMID:
19280533
17.

Appropriateness of colonoscopy in Europe (EPAGE II). Surveillance after polypectomy and after resection of colorectal cancer.

Arditi C, Gonvers JJ, Burnand B, Minoli G, Oertli D, Lacaine F, Dubois RW, Vader JP, Schusselé Filliettaz S, Peytremann-Bridevaux I, Pittet V, Juillerat P, Froehlich F; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):209-17. doi: 10.1055/s-0028-1119646. Epub 2009 Mar 11. Review.

PMID:
19280532
18.

Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer.

Arditi C, Peytremann-Bridevaux I, Burnand B, Eckardt VF, Bytzer P, Agréus L, Dubois RW, Vader JP, Froehlich F, Pittet V, Schusselé Filliettaz S, Juillerat P, Gonvers JJ; EPAGE II Study Group.

Endoscopy. 2009 Mar;41(3):200-8. doi: 10.1055/s-0028-1119626. Epub 2009 Mar 11. Review.

PMID:
19280531
19.

Colorectal cancer detection: how well do appropriateness criteria perform?

Gonvers JJ, Burnand B, Vader JP, Froehlich F.

Clin Gastroenterol Hepatol. 2009 Jul;7(7):807-8; author reply 808. doi: 10.1016/j.cgh.2009.02.013. Epub 2009 Feb 24. No abstract available.

PMID:
19245855
20.

Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.

Ciuffreda D, Comte D, Cavassini M, Giostra E, Bühler L, Perruchoud M, Heim MH, Battegay M, Genné D, Mulhaupt B, Malinverni R, Oneta C, Bernasconi E, Monnat M, Cerny A, Chuard C, Borovicka J, Mentha G, Pascual M, Gonvers JJ, Pantaleo G, Dutoit V.

Eur J Immunol. 2008 Oct;38(10):2665-77. doi: 10.1002/eji.200838336.

21.

Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection.

Helbling B, Overbeck K, Gonvers JJ, Malinverni R, Dufour JF, Borovicka J, Heim M, Cerny A, Negro F, Bucher S, Rickenbach M, Renner EL, Mullhaupt B; Swiss Hepatitis C Cohort Study.

Gut. 2008 Nov;57(11):1597-603. doi: 10.1136/gut.2007.142844. Epub 2008 Jul 14.

PMID:
18625696
22.

Drug safety in Crohn's disease therapy.

Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P.

Digestion. 2007;76(2):161-8. doi: 10.1159/000111031. Epub 2008 Feb 7. Review.

PMID:
18239408
23.

Pregnancy and breastfeeding in patients with Crohn's disease.

Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C.

Digestion. 2007;76(2):149-60. doi: 10.1159/000111030. Epub 2008 Feb 7. Review.

PMID:
18239407
24.

Extraintestinal manifestations of Crohn's disease.

Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P.

Digestion. 2007;76(2):141-8. doi: 10.1159/000111029. Epub 2008 Feb 7. Review.

PMID:
18239406
25.

Upper gastrointestinal Crohn's disease.

Mottet C, Juillerat P, Pittet V, Gonvers JJ, Michetti P, Vader JP, Felley C, Froehlich F.

Digestion. 2007;76(2):136-40. doi: 10.1159/000111028. Epub 2008 Feb 7. Review.

PMID:
18239405
26.

Maintenance of surgically induced remission of Crohn's disease.

Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ.

Digestion. 2007;76(2):130-5. doi: 10.1159/000111027. Epub 2008 Feb 7. Review.

PMID:
18239404
27.

Maintenance of medically induced remission of Crohn's disease.

Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F.

Digestion. 2007;76(2):116-29. doi: 10.1159/000111026. Epub 2008 Feb 7. Review.

PMID:
18239403
28.

Fibrostenotic Crohn's disease.

Froehlich F, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Gonvers JJ, Michetti P.

Digestion. 2007;76(2):113-5. doi: 10.1159/000111025. Epub 2008 Feb 7. Review.

PMID:
18239402
29.

Fistulizing Crohn's disease.

Felley C, Mottet C, Juillerat P, Pittet V, Froehlich F, Vader JP, Michetti P, Gonvers JJ.

Digestion. 2007;76(2):109-12. doi: 10.1159/000111024. Epub 2008 Feb 7. Review.

PMID:
18239401
30.

Severe and steroid-resistant Crohn's disease.

Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F.

Digestion. 2007;76(2):99-108. doi: 10.1159/000111023. Epub 2008 Feb 7. Review.

PMID:
18239400
31.

Mild-to-moderate active luminal Crohn's disease.

Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers JJ, Vader JP, Froehlich F, Felley C.

Digestion. 2007;76(2):92-8. doi: 10.1159/000111022. Epub 2008 Feb 7. Review.

PMID:
18239399
32.

EPACT II: project and methods.

Juillerat P, Froehlich F, Felley C, Pittet V, Mottet C, Gonvers JJ, Michetti P, Vader JP.

Digestion. 2007;76(2):84-91. doi: 10.1159/000111021. Epub 2008 Feb 7.

PMID:
18239398
33.

Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C.

Hora C, Negro F, Leandro G, Oneta CM, Rubbia-Brandt L, Muellhaupt B, Helbling B, Malinverni R, Gonvers JJ, Dufour JF; Swiss Hepatitis C Cohort Study Group.

Liver Int. 2008 Mar;28(3):370-6. Epub 2007 Nov 1.

PMID:
17976159
34.

Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study.

Wenger C, Bischof T, Gonvers JJ, Renner EL, Mullhaupt B.

Swiss Med Wkly. 2007 Jul 28;137(29-30):418-23.

PMID:
17705104
35.

A European view of diagnostic yield and appropriateness of colonoscopy.

Gonvers JJ, Harris JK, Wietlisbach V, Burnand B, Vader JP, Froehlich F; EPAGE Study Group.

Hepatogastroenterology. 2007 Apr-May;54(75):729-35.

PMID:
17591050
36.

Factors associated with the technical performance of colonoscopy: An EPAGE Study.

Harris JK, Froehlich F, Wietlisbach V, Burnand B, Gonvers JJ, Vader JP.

Dig Liver Dis. 2007 Jul;39(7):678-89. Epub 2007 Apr 16.

PMID:
17434349
37.

The appropriateness of colonoscopy: a multi-center, international, observational study.

Harris JK, Froehlich F, Gonvers JJ, Wietlisbach V, Burnand B, Vader JP.

Int J Qual Health Care. 2007 Jun;19(3):150-7. Epub 2007 Mar 8.

PMID:
17347317
38.

Endoscope once for any symptom at any age?

Froehlich F, Harris JK, Burnand B, Vader JP, Pittet V, Gonvers JJ.

Gastrointest Endosc. 2007 Feb;65(2):358-9; author reply 359. No abstract available.

PMID:
17259009
39.

Variations in colonoscopy practice in Europe: a multicentre descriptive study (EPAGE).

Harris JK, Vader JP, Wietlisbach V, Burnand B, Gonvers JJ, Froehlich F; Epage Study Group.

Scand J Gastroenterol. 2007 Jan;42(1):126-34.

PMID:
17190772
40.

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.

Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver.

Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43.

PMID:
17162245
41.

HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.

Helbling B, Jochum W, Stamenic I, Knöpfli M, Cerny A, Borovicka J, Gonvers JJ, Wilhelmi M, Dinges S, Müllhaupt B, Esteban A, Meyer-Wyss B, Renner EL; Swiss Association for the Study of the Liver (SASL).

J Viral Hepat. 2006 Nov;13(11):762-9.

PMID:
17052276
42.

Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach--EPACT.

Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P.

Digestion. 2006;73(4):237-48. Epub 2006 Aug 29.

PMID:
16940727
43.

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.

Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL; Swiss Association for the Study of the Liver (SASL).

J Viral Hepat. 2006 Jul;13(7):457-65.

PMID:
16792539
44.

Current sedation and monitoring practice for colonoscopy: an International Observational Study (EPAGE).

Froehlich F, Harris JK, Wietlisbach V, Burnand B, Vader JP, Gonvers JJ; EPAGE Study Group.

Endoscopy. 2006 May;38(5):461-9.

PMID:
16767580
45.

Use, appropriateness, and diagnostic yield of screening colonoscopy: an international observational study (EPAGE).

Burnand B, Harris JK, Wietlisbach V, Froehlich F, Vader JP, Gonvers JJ.

Gastrointest Endosc. 2006 Jun;63(7):1018-26.

PMID:
16733119
46.

Appropriateness of colorectal cancer screening: appraisal of evidence by experts.

Bridevaux IP, Silaghi AM, Vader JP, Froehlich F, Gonvers JJ, Burnand B.

Int J Qual Health Care. 2006 Jun;18(3):177-82. Epub 2006 Apr 7.

PMID:
16603584
47.

[Hepatology].

Mondada D, Pache I, Leopold K, Thorens J, Moradpour D, Gonvers JJ.

Rev Med Suisse. 2006 Jan 18;2(49):218-20, 223-6, 228-30. Review. French.

PMID:
16493965
48.

Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection.

Dutoit V, Ciuffreda D, Comte D, Gonvers JJ, Pantaleo G.

Eur J Immunol. 2005 Dec;35(12):3493-504.

49.

Gastroenterologists overestimate the appropriateness of colonoscopies they perform: an international observational study.

Vader JP, Wietlisbach V, Harris JK, Burnand B, Froehlich F, Gonvers JJ.

Endoscopy. 2005 Sep;37(9):840-6.

PMID:
16116535
50.

ASGE versus EPAGE versus diagnostic yield: a level playing field, please!

Vader JP, Froehlich F, Burnand B, Gonvers JJ.

Am J Gastroenterol. 2005 Aug;100(8):1892; author reply 1892-3. No abstract available.

PMID:
16086727

Supplemental Content

Loading ...
Support Center